Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseasesle

Basit Öğe Kaydı
dc.authoridCoşkun, Belkıs Nihan/0000-0003-0298-4157
dc.authoridYıldız, Fatih/0000-0003-3628-8870
dc.authoriderken, eren/0000-0001-6902-624X
dc.authoridYazıcı, Ayten/0000-0003-2167-4509
dc.authoridAksu, Kenan/0000-0001-8889-2688
dc.authoridOzen, Gulsen/0000-0002-5423-393X
dc.authoridKaradag, Omer/0000-0002-3443-3117
dc.authorwosidCoşkun, Belkıs Nihan/AAG-7155-2021
dc.authorwosidEmmungil, Hakan/J-9960-2019
dc.authorwosidYıldız, Fatih/P-2555-2018
dc.authorwosidKimyon, Gezmiş/AAY-4798-2020
dc.authorwosiderken, eren/L-3219-2019
dc.authorwosidYazıcı, Ayten/AAT-3636-2020
dc.authorwosidCefle, Ayse/AAT-3653-2020
dc.contributor.authorYilmaz, Neslihan
dc.contributor.authorEmmungil, Hakan
dc.contributor.authorGucenmez, Sercan
dc.contributor.authorOzen, Gulsen
dc.contributor.authorYildiz, Fatih
dc.contributor.authorBalkarli, Ayse
dc.contributor.authorKimyon, Gezmis
dc.date.accessioned2024-06-12T11:03:07Z
dc.date.available2024-06-12T11:03:07Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective. To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics. Results. We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis. Conclusion. Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.en_US
dc.identifier.doi10.3899/jrheum.150065
dc.identifier.endpage1666en_US
dc.identifier.issn0315-162X
dc.identifier.issn1499-2752
dc.identifier.issue9en_US
dc.identifier.pmid26178288en_US
dc.identifier.scopus2-s2.0-84940707172en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1661en_US
dc.identifier.urihttps://doi.org/10.3899/jrheum.150065
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21537
dc.identifier.volume42en_US
dc.identifier.wosWOS:000360733600020en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJ Rheumatol Publ Coen_US
dc.relation.ispartofJournal Of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHEMORRHAGIC CYSTITISen_US
dc.subjectMESNAen_US
dc.subjectRHEUMATIC DISEASESen_US
dc.subjectInduced Hemorrhagic Cystitisen_US
dc.subjectIntravenous Cyclophosphamideen_US
dc.subjectBladder Toxicityen_US
dc.subjectControlled-Trialen_US
dc.subjectLupus Nephritisen_US
dc.subjectWegeners-Granulomatosisen_US
dc.subjectPulse Cyclophosphamideen_US
dc.subjectOral Cyclophosphamideen_US
dc.subjectDouble-Blinden_US
dc.subjectFollow-Upen_US
dc.titleIncidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseasesleen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu